Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-56. (Cancelled)

- 57. (Previously presented) The composition of claim 74, wherein the chemokine polypeptide comprises an amino acid sequence selected from the group consisting of:
 - (aa) SEQ ID NO:1;
 - (ab) SEQ ID NO:1 from amino acid 20 amino acid 328;
 - (ac) SEQ ID NO:2 from amino acid 21 to amino acid 328; and
 - (ad) SEQ ID NO:3.
- 58. (Previously Presented) The composition of claim 57 wherein the chimeric polypeptide comprises an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:1;
- (b) the amino acid sequence of SEQ ID NO:1 from amino acid 20 to amino acid 328; and
 - (c) the amino acid sequence of SEQ ID NO:1 from amino acid 22 to amino acid 328.
- 59. (Previously presented) The composition of claim 57 wherein the chemokine polypeptide comprises an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:3.
- 60. (Previously Presented) The composition of claim 57 wherein the chemokine polypeptide comprises the amino acid sequence of SEQ ID NO:1.
- 61. (Previously Presented) The composition of claim 57 wherein the chemokine polypeptide comprises the amino acid sequence of SEQ ID NO:3.

- 62. (Previously Presented) The composition of claim 57, further comprising a pharmaceutically acceptable carrier.
- 63. (Previously presented) The composition of claim 57 wherein the chemokine polypeptide comprises SEQ ID NO:1 from amino acid 20 to amino acid 328.
- 64. (Previously Presented) The composition of claim 57 wherein the chemokine polypeptide comprises SEQ ID NO:1 from amino acid 21 to amino acid 328.
- 65. (Currently amended) The composition of claim 57 wherein the chemokine polypeptide comprises consists essentially of SEQ ID NO:1 from amino acid 22 to amino acid 328.
- 66. (Previously presented) The composition of claim 57 wherein the chemokine polypeptide consists of SEQ ID NO:3 from amino acid 20 to amino acid 326.
 - 67. (Currently amended) A polypeptide produced according to a process comprising:
- (a) growing a culture of a host cell in a suitable culture medium, wherein the host cell has been transformed with a polynucleotide comprising at least one expression control sequence, wherein the polynucleotide encodes a chimeric polypeptide, the chimeric polypeptide comprising at least one chemokine polypeptide covalently attached to at least one heterologous polypeptide, wherein the heterologous polypeptide is an Fc polypeptide, wherein the chemokine polypeptide comprises
 - (a) SEQ ID NO:1 from amino acid 22 to amino acid 328 and,
 - (b) purifying said polypeptide from the culture.
- 68. (Previously Presented) The polypeptide of claim 67 wherein the chemokine polypeptide comprises SEQ ID NO:1.
- 69. (Previously Presented) The polypeptide of claim 67 wherein the chemokine polypeptide comprises SEQ ID NO:1 from amino acid 20 to amino acid 328.

- 70. (Previously Presented) The polypeptide of claim 67 wherein the chemokine polypeptide comprises SEQ ID NO:1 from amino acid 21 to amino acid 328.
- 71. (Currently amended) The polypeptide of claim 67 wherein the chemokine polypeptide consists essentially of comprises SEQ ID NO:1 from amino acid 22 to amino acid 328.
- 72. (Previously Presented) The polypeptide of claim 67 wherein the chemokine polypeptide comprises SEQ ID NO:3.
- 73. (Previously presented) The polypeptide of claim 67 wherein the chemokine polypeptide consists of SEQ ID NO:3 from amino acid 20 to amino acid 326.
- 74. (Previously presented) A composition comprising a chimeric polypeptide, the chimeric polypeptide comprising at least one chemokine polypeptide covalently attached to at least one heterologous polypeptide, wherein the heterologous polypeptide is an Fc polypeptide, wherein the chemokine polypeptide comprises SEQ ID NO:1 from amino acid 22 to amino acid 328.